期刊文献+

高效液相色谱法测定盐酸伊立替康注射液的含量 被引量:2

Content Determination of Irinotecan Hydrochloride Injection by HPLC
下载PDF
导出
摘要 目的建立测定盐酸伊立替康注射液中盐酸伊立替康含量的高效液相色谱法。方法采用Agilent HC-C_(18)柱(250 mm×4.6 mm,5μm),以磷酸盐缓冲液(称取无水磷酸二氢钠2.43 g和辛烷磺酸钠1.66 g,溶于1 000 mL水中)-甲醇-乙腈(57:25:18)为流动相,柱温为40℃,流速为1.5 mL/min,检测波长为255 nm。结果盐酸伊立替康质量浓度在0.1831~1.464 7 g/L范围内与峰面积呈良好线性关系(r=0.9994,n=7),平均回收率为100.33%,RSD=0.46%(n=9)。结论该法准确、简便、重复性好,可用于盐酸伊立替康注射液的含量测定。 Objective To establish a high performance liquid chromatography(HPLC) method for the content determination of Irinotecan Hydrochloride Injection. Methods The HPLC method was performed on the Agilent HC- C18 column(250 mm ×4. 6 mm, 5 μm) with the mobile phase of phosphate buffer (dissolving anhydrous sodium dihydrogen phosphate 2.43 g and 1-octanesulfonic acid sodium 1.66 g in 1 000 mL of water)-methanol-acetonitrile (57:25:18). The column temperature was 40℃, the flow rate was 1.5 mL/min and the detective wavelength was 255 nm. Results The linear range of irinotecan hydrochloride was 0. 183 1- 1. 464 7 mg/mL(r=0. 999 4, n =7), the average recovery rate was 100. 33%, RSD was 0.46% (n =9). Conclusion The method is accurate and simple with good repeatability, which can be used for the content determination of Irinotecan Hydrochloride Injection.
出处 《中国药业》 CAS 2014年第11期38-39,共2页 China Pharmaceuticals
关键词 盐酸伊立替康 高效液相色谱法 含量测定 Irinotecan Hydrochloride high performance liquid chromatography content determination
  • 相关文献

参考文献5

二级参考文献21

  • 1[1]Anonymous. Irinotecan. [J/CD] Pharma Projects, 1996, (5): a1404-a1405.
  • 2[2]Wiseman LR, Markham A. Irinotecan--A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer [J]. Drugs, 1996, 52(4)∶606-623.
  • 3[3]Anonymous. Irinotecan--Antineoplastic [J]. Drugs Future, 1996, 21(3)∶316-317.
  • 4Takiguchi Y, Moriya T, A saka-Amano Y, et al. Phase Ⅱ study of Weekly irinotecan and cisp latin for refractory or recurrent nonsmall cell lu - ng cancer[J]. Lung Cancer, 2007, 58 (2) : 253 - 259.
  • 5Suzuki S, Harada N, Takeo Y, et al. B i-weekly irinotecan hydro2 ehh, ride and cisp latin as a second-line chemotherapy for patients with advanc ed gastrie cancer[J].Gan To Kagaku Ryoho, 2007,34(13): 2 245 - 2 248.
  • 6Sumiyoshi H ,Fujiwara Y,Ohune T,et al. High-performance liquid chromatographic determination of ifinotecan( CPT-11 ) and its active metabolite( SN-38 ) in human plasma [ J ]. Chromatogr B,1995,670(2) :309.
  • 7Rivory L P, Robert. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitatlon of the carboxylate and lactone forms of the camptothecin derivative irinoteean, CPT-11 ,and its metabolite SN-38 in plasma [J]. Chromatogr B,1994,661 (1) :133.
  • 8Akinobu K, Norimasa K. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolite SN-38 and SN-38 glueuronide in rat plasma with a fully automated on-line solid-phase extraction system, Prospekt [ J ]. Chromatogr B, 1999,724:335.
  • 9Sparreboom A, de Bruijn P, Maja JA de Jonge ,et al. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces[J]. Chromatography B,1998 312:225-235.
  • 10朱雅俊,梁国华,吴建华.伊立替康联合5-Fu/CF持续静脉滴注治疗晚期大肠癌的临床观察[J].工企医刊,2007,20(4):1-2. 被引量:2

共引文献29

同被引文献16

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部